MEDIMMUNE LICENSES RIGHTS FOR ANTIBODY PROGRAM FROM GSK

MedImmune announced that it has licensed worldwide rights from GlaxoSmithKline (GSK) to develop certain antistaphylococcal monoclonal antibodies (MAbs). The program includes BSYX-A110, which is in Phase II clinical development for the prevention of serious bloodstream infections caused by Staphylococcus in low-birthweight infants.

Under the terms of the agreement, MedImmune will pay GSK an upfront payment upon signing as well as potential milestone payments and royalties on future marketed products. MedImmune has also assumed responsibility for future milestone and royalty payment obligations to Biosynexus, from which GSK originally licensed the BSYX-A110 antibody and related rights in 2002.